WASHINGTON — House Oversight Chairman Elijah Cummings (Md.) isn’t the only newly empowered Democrat with his eyes on drug makers.

Rep. Diana DeGette of Colorado, the newly minted chair of the Energy and Commerce Committee’s oversight arm, is also planning to haul industry CEOs before her own panel, she said Wednesday at a briefing with reporters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I might subscribe if wasn’t for the tease of a gov’t oversight committee article, which last I looked you didn’t pay for on a free perhaps no longer open internet.
    What you produce warrents renumeration but not this….Soooooo! WOT

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy